1/6 Yes -- this article is over 3 years old now and I then presented on Remnant Cholesterol (RC) at LC Denver earlier that year.
In rereading this article, there are a few things I'd update -- but the general focus on systemic outcome relevance still holds...
In rereading this article, there are a few things I'd update -- but the general focus on systemic outcome relevance still holds...
https://twitter.com/raphaels7/status/1418474789417668613
2/6 A more updated article on this, along with further thoughts, can be found here: cholesterolcode.com/thoughts-regar…
3/6 If you read nothing else, check out this section from the article, and why I'm so vocal about *not* looking only at #ApoB (which lumps non-LDL and LDL) together.
Again -- and with emphasis -- this is part of the larger hypothesis. But all the more reason to research it...
Again -- and with emphasis -- this is part of the larger hypothesis. But all the more reason to research it...
4/6 More recently, there's greater focus on Remnant Cholesterol, which I consider very encouraging -- particularly where stratifying out against LDL in particular. (HT @shashiiyengar)
academic.oup.com/eurheartj/adva…
academic.oup.com/eurheartj/adva…
5/6 But ideally, we'd look to populations with very high LDL, yet low RC (such as #LMHRs) to better determine if this is indeed more systemic to lipid metabolism vs inherent atherogenicity of the lipoprotein (and yes, per @raphaels7's mention, I think it's much more the former)
6/6 And of course, we're in the process of putting together a study on #LMHRs right now via the CitizenScienceFoundation.org -- so hopefully we'll have some very relevant data on that soon.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
